Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis.
- DOI
- 10.1016/j.ejca.2026.116907
- Published
- 2026 Aug 26
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2026.116907,
title = {Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis.},
author = {Li G and Pu Y and Chen C and Kesselheim AS and Tibau A},
year = {2026},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2026.116907},
url = {https://doi.org/10.1016/j.ejca.2026.116907}
}RIS
TY - JOUR TI - Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis. AU - Li G AU - Pu Y AU - Chen C AU - Kesselheim AS AU - Tibau A PY - 2026 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2026.116907 UR - https://doi.org/10.1016/j.ejca.2026.116907 ER -
APA
G, L., Y, P., C, C., AS, K., & A, T. (2026). Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2026.116907
Source records
- pubmed · retrieved 2026-09-25T06:55:01.476Z